- Home
- D vs REGN Comparison
D vs REGN Comparison
Compare D & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- D
- REGN
- Stock Information
- Founded
- D 1983
- REGN 1988
- Country
- D United States
- REGN United States
- Employees
- D N/A
- REGN N/A
- Industry
- D
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- D
- REGN Health Care
- Exchange
- D Nasdaq
- REGN Nasdaq
- Market Cap
- D 51.5B
- REGN 59.5B
- IPO Year
- D N/A
- REGN 1991
- Fundamental
- Price
- D $60.03
- REGN $568.20
- Analyst Decision
- D Hold
- REGN Buy
- Analyst Count
- D 7
- REGN 23
- Target Price
- D $59.57
- REGN $794.83
- AVG Volume (30 Days)
- D 4.7M
- REGN 991.3K
- Earning Date
- D 10-31-2025
- REGN 10-30-2025
- Dividend Yield
- D 4.45%
- REGN 0.62%
- EPS Growth
- D 86.34
- REGN 5.03
- EPS
- D 2.99
- REGN 39.67
- Revenue
- D $15,227,000,000.00
- REGN $14,214,200,000.00
- Revenue This Year
- D $11.04
- REGN N/A
- Revenue Next Year
- D $6.20
- REGN $4.97
- P/E Ratio
- D $20.07
- REGN $14.32
- Revenue Growth
- D 5.29
- REGN 5.38
- 52 Week Low
- D $48.07
- REGN $476.49
- 52 Week High
- D $62.46
- REGN $1,170.58
- Technical
- Relative Strength Index (RSI)
- D 53.19
- REGN 50.07
- Support Level
- D $57.56
- REGN $552.98
- Resistance Level
- D $59.57
- REGN $588.70
- Average True Range (ATR)
- D 0.98
- REGN 16.19
- MACD
- D -0.15
- REGN -3.04
- Stochastic Oscillator
- D 50.82
- REGN 26.70
About D Dominion Energy Inc.
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion is constructing a rate-regulated 5.2 GW wind farm off the Virginia Beach coast.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).